MedTrace Logo

A Study of AL8326 in Healthy Subjects

NCT07132957 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-08-20

No results posted yet for this study

Summary

This experiment plans to enroll 6-8 healthy male subjects in China, and ultimately collect complete test samples and data from at least 6 subjects as the standard. On the first day of the experiment, each subject orally took a single dose of \[14C\] AL8326 oral formulation containing approximately 60mg (200 μ Ci). During the experiment, whole blood, plasma, urine, and fecal samples were collected at designated time points/time periods.

Conditions

Interventions

DRUG

14C-labeled AL8326

Oral, About 60mg (200μCi) of 14C-labeled AL8326

Sponsors & Collaborators

  • Advenchen Laboratories Nanjing Ltd.

    lead INDUSTRY

Principal Investigators

  • LiYan Miao · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-21
Primary Completion
2025-05-17
Completion
2025-05-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07132957 on ClinicalTrials.gov